Abstract: Pregnancy-associated breast cancer is defined as invasive breast cancer diagnosed during gestation, within 1 year postpartum, or during lactation. Of particular interest is the treatment of invasive breast cancer during gestation; standard treatment protocols must take into account the health of the fetus. This article reviews the literature and emerging data regarding the treatment of pregnancy-associated breast cancer. Existing staging and treatment practices need slight modification in the setting of pregnancy. The timing of surgery and the administration of cytotoxic chemotherapy must take into account age of gestation, but these modalities are safe in pregnancy.
P regnancy-associated breast cancer (PABC) is defined as invasive breast cancer diagnosed during gestation, within 1 year postpartum, or during lactation.
1 Although PABC is rare, the incidence of breast cancer during pregnancy is increasing, likely as result of the trend toward women's delaying child bearing to advanced maternal ages. 2 Termination of pregnancy has not been shown to improve survival. [3] [4] [5] Of particular interest is the treatment of invasive breast cancer during gestation, because standard treatment protocols must take into account the health of the fetus. It is fortunate that existing staging and treatment practices need only slight modification in the setting of pregnancy. The timing of surgery and the administration of cytotoxic chemotherapy must take into account age of gestation, but these modalities are safe in pregnancy. Clinicians' understanding of the true risk that PABC confers on a patient is evolving.
Diagnosis
PABC has been associated with a significant delay in diagnosis. 6 Common presenting complaints in PABC include a painless palpable mass, thickening of the skin, or asymmetrical swelling of the breast. Patients may reasonably conclude that such findings could be the result of normal physiologic changes related to pregnancy. Normal physiologic changes such as increased density of breast tissue also can make masses more difficult to palpate.
If a mammogram is performed first to evaluate changes in the breast or a palpable mass, then one can expect approximately an 86% sensitivity during pregnancy. 1 Mammography is safe in pregnancy because the radiation exposure to the fetus, particularly if the abdomen is shielded, is not sufficient to cause harm. A palpable mass should be further examined using ultrasound, another safe modality in pregnancy. Typically, ultrasound is used to distinguish solid from cystic masses. Magnetic resonance imaging (MRI) of the breast is not recommended because it requires gadolinium contrast and prone positioning. 6 Core biopsy is the recommended procedure for establishing a diagnosis, because fine-needle aspiration can be unreliable and technically difficult in the setting of pregnancy. Tissue should be sent for standard determination of receptor status. In addition, given the higher incidence of triple-negative cancers and the age at which most women are diagnosed as having PABC, genetic counseling and consideration for mutation testing, especially for BRCA1 and BRCA2, should be performed. 7, 8 Further imaging studies should be ordered judiciously, balancing how they would affect management of the disease and the risk to the fetus. 9 Additional staging recommendations include mammography of the contralateral breast, chest radiography, and liver ultrasound. 7 Radiography exposes the shielded fetus to minimal amounts of ionizing radiation. 10 MRI of the brain without gadolinium contrast for patients with neurological symptoms is recommended.
11 MRI without contrast also is preferred to evaluate for bone metastases when clinically indicated. been used in pregnancy. 12, 13 A reduction in the dose of tracer used and an increase in imaging time appear to minimize the radiation dose to the fetus.
14 Confirmation of gestational age using early obstetric ultrasound is an important standard evaluation and is key to treatment planning, particularly in the multidisciplinary setting. Early involvement of a maternofetal medicine specialist also is advisable for the pregnant patient with breast cancer.
Breast Cancer Surgery in Pregnancy
Gestational age at diagnosis often dictates the surgical approach. If possible, surgery should be performed early in the second trimester to minimize the risk of preterm labor and because the period of organogenesis is complete. 15 General anesthesia is considered safe in pregnancy, with no currently used anesthetic agents associated with teratogenic effects at standard concentrations for any gestational age. 16, 17 Nonobstetric surgical procedures at or beyond the point of fetal viability have a low risk of intraoperative or immediate postoperative obstetric complications, but they do confer increased risk of preterm delivery. 15, 16 Perioperative and intraoperative fetal monitoring recommendations also are based on gestational age at the time of surgery. Patients who present in the first trimester may proceed directly to surgery after appropriate discussion of potential risks to the fetus; perioperative fetal heart tone evaluation is not recommended for these patients. 18 For a second trimester fetus that is previable, generally considered to be before 24 weeks' gestation, fetal heart tone assessment by Doppler ultrasound preand postoperatively is recommended. For women with viable fetuses, surgery should be performed at a facility offering neonatal and pediatric services and an obstetric provider who is readily available. Electronic fetal heart rate and contraction monitoring with a trained obstetrical nurse should be done intraoperatively as well as pre-and postprocedure. 17 Women diagnosed in the third trimester may defer surgery until postpartum and may consider early induction of labor to avoid excessive treatment delays. Surgery during later gestational age must account for the gravid uterus during patient positioning. Timing of surgery discussions should include a maternofetal medicine specialist and an obstetrician to discern the need for early delivery in patients who present late in pregnancy.
The use of breast conservation also may be directed by gestational age. 19 Surgical treatment for pregnant patients traditionally was limited to modified radical mastectomy; however, breast conservation may be an option for patients presenting with limited in-breast disease, particularly in the second or third trimester, or if chemotherapy is indicated and initiated during pregnancy, allowing subsequent radiation to be deferred to the postpartum period. Adjuvant radiation is absolutely contraindicated in pregnancy, so breast conservation generally is not recommended in the first trimester unless the patient is scheduled for adjuvant chemotherapy in pregnancy. Breast-conserving surgery requires careful multidisciplinary planning because of the contraindications for radiation in pregnancy.
Clinical stage also determines surgical decisions in patients with breast cancer. Mastectomy may be required in patients with multifocal disease or locally advanced breast cancer at presentation, regardless of pregnancy. Axillary surgery for breast cancer during pregnancy has evolved, however. In patients with regional nodal involvement on physical examination or axillary ultrasound and confirmed by percutaneous biopsy, axillary lymph node dissection without attempted sentinel lymph node (SLN) biopsy is the recommended option. 20, 21 Although blue dye mapping with lymphazurin or methylene blue is contraindicated in pregnancy, technetium-99 sulfur colloid for SLN surgery is safe and feasible in the second and third trimesters of pregnancy for clinically node-negative women. 22 Despite American Society of Clinical Oncology guidelines discouraging SLN biopsy in pregnancy, evidence from the literature estimates that uterine radiation exposure for a fetus during SLN surgery is one-fifth of that received from daily background radiation, lending credence to the safety of SLN surgery during pregnancy. 20, 23 If the SLN is positive for metastasis, axillary lymph node dissection is again considered.
Given the trend toward prophylactic mastectomies, especially among young patients with breast cancer, it is important to note that elective or prophylactic procedures should be deferred to the postpartum period. 24, 25 The American Society of Anesthesiologists recommends that prophylactic or reconstructive breast surgery not be performed during pregnancy to minimize risks to the fetus and exposure to anesthetic agents; however, one small single-institution series has suggested tissue expander reconstruction. 26, 27 Systemic Therapy
The treatment goals and indications for systemic therapy remain the same in pregnant patients with breast cancer, with some exceptions. The timing and sequence of treatment may be altered depending on how far along in gestation the patient is at the time of diagnosis. It also is important to understand that treatment delays to the postpartum period generally do not afford a survival advantage. 28 A 2012 consensus recommendation suggested that neoadjuvant cytotoxic chemotherapy treatment regimens be the same as those used in nonpregnant women 29 ; however, common systemic agents, including anthracyclines, taxanes, and trastuzumab, 30, 31 used in breast cancer treatment protocols will cross the placental barrier. Given the risk of cytotoxic agents and fetal malformations, these systemic agents are contraindicated in the first trimester. Neoadjuvant chemotherapy should be considered when indicated and when the pregnancy has progressed beyond the first trimester; otherwise, surgery should proceed first if possible to avoid delay in treatment. Adjuvant chemotherapy generally is started after 12 weeks' gestation in women who undergo surgery in the first trimester. 6 To avoid the risk of cytopenias, particularly neutropenia at the time of delivery, chemotherapy is typically not administered following 35 weeks' gestation. 7 There are good published data regarding the safety of doxorubicin and cyclophosphamide in pregnancy, typically in conjunction with fluorouracil. Case series studies indicate a rate of congenital abnormalities near the national average in children born to mothers who received fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy during pregnancy. One early prospective trial using FAC resulted in no congenital abnormalities in 24 patients treated. 32 Patients received a median of four cycles of chemotherapy. The dose of doxorubicin used was 50 mg/m 2 and that of cyclophosphamide was 500 mg/m 2 . Newborn Apgar scores were ≥9 at 5 minutes postpartum. Gestational age ranged from 33 to 40 weeks, with an average of 38 weeks. One infant was born below the 10th percentile for birth weight. No use of growth factor support was reported, and supportive antiemetic therapy included ondansetron, promethazine, and prochlorperazine.
A trial using FAC in 57 patients reported only 1 newborn with Down syndrome and 1 with clubfoot. 33 Most of the patients were treated with four cycles of therapy, with a median gestational age of 23 weeks at initiation of chemotherapy. A follow-up article reported on the combined outcomes of these two previous trials. 34 The authors reported only one additional child with a congenital abnormality, ureteral reflux, after in utero chemotherapy exposure. The median gestational age was 37 weeks, and the average birth weight was 2.9 kg. One child was born preterm, weighed 1.39 kg, and required a 2-month stay in the neonatal intensive care unit.
A European group reported on 28 pregnant patients who received chemotherapy for breast cancer-7 in the neoadjuvant setting, 17 in the adjuvant setting, and 4 with palliative intent with metastatic cancer. 35 Sixteen of these patients received anthracycline-based chemotherapy (either epirubicin and cyclophosphamide or doxorubicin and cyclophosphamide); 12 received cyclophosphamide, methotrexate, and fluorouracil. There were no fetal abnormalities. One infant at birth weighed 1.4 kg as a result of placental insufficiency. Birth weights otherwise ranged from 1.4 to 3.5 kg. The median gestational age at delivery was 37 weeks.
The observational study of Loibl et al included 413 patients with a primary diagnosis of early breast cancer during pregnancy who were treated in seven European centers. One hundred ninetyseven (48%) patients received chemotherapy during pregnancy and nearly 90% of patients received an anthracycline. 36 Preterm labor or premature rupture of membranes was more common when chemotherapy was given during pregnancy without resulting in more preterm deliveries. In contrast to other studies, this study reported more complications in the group of infants exposed to chemotherapy than in the group not exposed to chemotherapy; however, most complications were reported in babies who were delivered prematurely, irrespective of exposure to chemotherapy. The proportion of malformations in this study was not different from the general population.
In general, taxanes have been withheld in treatment protocols in PABC; however, evidence regarding their safety is growing. A review of case reports of taxane use in pregnancy, including 27 cases of breast cancer, identified 2 cases of neonatal acute respiratory distress with paclitaxel exposure. 37 One infant was born with pyloric stenosis to a mother who had been exposed to both paclitaxel and docetaxel. No fetal demise was noted. In a retrospective study, Cardonick and colleagues reported on 15 women who were exposed to taxanes; 12 of these patients were treated for breast cancer. 38 There were no differences in gestational age at delivery, growth restriction, birth weight, or rate of congenital malformations. Loibl et al did not find evidence that taxanes affected birth weights in the European multicenter study. 36 A multicenter, case-control study detailed the pregnancy outcomes of 129 children born to women with any diagnosis of cancer. 39 They were compared with a matched-for-gestationalage group of children born to mothers without a cancer diagnosis. The distribution of specific type of malignancy was not provided; however, the article did report the various agents that were received. Ninety-six patients received chemotherapy at some point during the treatment of malignancy, 78 patients received anthracyclines, and 22 received taxanes. The number of cycles of chemotherapy that women received ranged from 1 to 10. The timing of chemotherapy (adjuvant vs neoadjuvant) and dose were not reported. One child was born to a mother who did receive trastuzumab. The outcomes for this child and patient were not specifically reported. Women who were exposed to chemotherapy did experience a 61.2% rate of preterm births. The general average among participating countries was 6.8% to 8%. Gestational age at delivery was associated with an improvement in cognitive development. For each week increase in gestational age, the average cognitive function scores improved by 2.8 and 3.1 points, respectively, in the chemotherapy exposed and nonexposed groups. Because participants were matched based upon gestational age, this effectively removed this confounding factor. Still, no statistical difference was seen in cognitive development between the two groups, as measured by Bayley II or III scores.
Despite the safety of cytotoxic chemotherapy in the second and third trimesters of pregnancy, other systemic options used in nonpregnant are generally not recommended at all during pregnancy. Antiestrogen therapies such as aromatase inhibitors or fulvestrant are contraindicated in pregnancy. 6 Tamoxifen is pregnancy risk category D. Trastuzumab has been associated with fetal oligohydramnios and therefore is not given during pregnancy. 6 Because of its similar mechanism of action, pertuzumab also is not given during pregnancy. There are no reports of its use in pregnant patients.
Supportive care for patients undergoing cytotoxic chemotherapy is important. Growth factor, such as filgrastim and pegfilgrastim, carries a pregnancy risk factor of C. 38 It also has been found in breast milk. Chemotherapy is not recommended in the first trimester; therefore, use of growth factor to support neutrophil counts would not be indicated during fetal organogenesis. Growth factor has been safely used in the setting of dosedense chemotherapy. 38 In general, antiemetics are safe for use in pregnancy. Ondansetron has been widely studied and is not associated with an increase in poor fetal outcomes. Dexamethasone is generally not recommended because of the risk of cleft palate and attention-deficit/hyperactivity disorder associated with its use. Alternative agents such as methylprednisolone are preferred. 7 Our institutional preference is to use doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 in both the adjuvant and neoadjuvant settings. Generally speaking, a dose-dense schedule is not used. The risk of cytopenias, especially thrombocytopenia, antepartum is reduced with alternative schedules. In addition, although growth factor has been reported to be safe, there is not enough evidence for its routine use. Taxanes typically have been held until the postpartum period; however, as noted above, their use does not appear to be associated with an increased risk of fetal malformations.
Disease Characteristics and Prognosis
Studies vary as to the contribution pregnancy itself makes to prognosis. In general, PABC is less frequently hormone receptor positive. The frequency of human epidermal growth factor receptor 2 positivity varies in the literature. The tumor microenvironment also is notably different in PABC. Tumor-infiltrating lymphocytes are more numerous. Although programmed cell death receptor 1expression was similar between tumors in PABC and non-PABC, evidence has demonstrated increased programmed cell death-ligand 1 expression on tumors in PABC. 40 Two separate groups showed that patients with PABC presented with more advanced disease, larger tumors, and increased proportion of receptor-negative cancers. 41, 42 One of the studies found a higher proportion of inflammatory breast cancers; however, both groups found that pregnancy was an independent risk factor for poor prognosis in multivariate analyses. Zhang et al found a trend toward worse prognosis that did not reach statistical significance. 43 Data are suggestive of different-if not worse-tumor biology; PABC demonstrated a trend of greater risk of lymph node involvement independent of tumor size that did not reach statistical significance. 44 Several case-control studies conducted by other authors have found no such worsening of prognosis. [45] [46] [47] Others have demonstrated a potentially improved prognosis. 48 Amant et al described a series of patients with PABC, excluding those diagnosed in the postpartum setting. Adjusting for a variety of factors, including age, stage, grade, hormone receptor status, human epidermal growth factor receptor 2 status, and type of chemotherapy, the hazard ratios were not statistically significant. 5 A large retrospective analysis was performed on 668 cases of breast cancer, 104 of which were PABC. 28 The purpose of the study was to compare outcomes, such as locoregional recurrence, rate of distant metastases, and overall survival, among young women (aged 35 y and younger). Overall, there were no statistically significant differences in these outcomes between the two groups. The article also reported the effect of either delaying diagnosis or postponing treatment. There was a trend toward improved overall survival at 5 years (P = 0.068) for those who received some treatment during pregnancy. A meta-analysis of 30 studies, however, seems to contradict these findings and showed an increased risk of death in PABC, which was even more pronounced if the cancer was diagnosed in the postpartum setting. 49 Although the exact contribution that pregnancy makes to outcomes is not clear, pregnant patients do present with later-stage disease. In addition, treatment delays can have a negative effect on outcome.
Conclusions
Any pregnant patient who presents with signs or symptoms suggestive of breast cancer must be evaluated promptly. PABC is associated with a delay is diagnosis and treatment delays worsen a patient's prognosis. Existing staging and treatment practices need slight modification in the setting of pregnancy. The timing of surgery and the administration of cytotoxic chemotherapy must take into account age of gestation, but these modalities are safe in pregnancy. Chemotherapy can be given during second and third trimesters but should be discontinued by 35 weeks. Our understanding of the true risk that PABC confers on a patient is evolving. Studies seem to indicate more aggressive tumor biology; however, data conflict as to the contribution of PABC to overall survival and other treatment outcomes.
